Shopping Cart 0
Cart Subtotal
USD 0

Shionogi & Co Ltd (4507) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The company's core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infection, immunity and cancer pain. Shionogi also sells, distributes and provides information about diagnostic products in the fields of infectious diseases, cardiovascular diseases and allergies. The company operates a network of subsidiaries, branches, sales offices manufacturing plants and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd (4507)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Venture Financing 17

Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17

Partnerships 18

Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18

Kyoto University and Shionogi Enter into Research Agreement 19

DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20

PharmaIN Enters into Agreement with Shionogi 21

Shionogi and UMN Pharma Enter into Agreement 22

Clinigen Enters into Agreement with Shionogi 23

Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25

FunPep Enters into Research Agreement with Shionogi 27

Shionogi Enters into Research Agreement with NB Health Labs 28

Shionogi Enters into Research Agreement with Nissan Chemical Industries 29

Mundipharma Enters into Distribution Agreement with Shionogi 30

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32

Shionogi to Enter into Agreement with TB Alliance 33

Kyoto University and Shionogi Enter into R&D Agreement 34

Licensing Agreements 35

Shionogi Enters into Licensing Agreement with Rohto Pharma 35

Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 36

Pharmbio Korea Enters into Licensing Agreement with Shionogi 37

Ophirex Enters into Licensing Agreement with Eli Lilly and Shionogi 38

Duchesnay Receives Rights for Osphena from Shionogi 39

Shionogi Enters into Licensing Agreement with University of Tokushima 40

F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 41

Shionogi Enters into Licensing Agreement with PeptiDream 42

Shionogi Enters into Licensing Agreement with FunPep 43

Shionogi Enters into Licensing Agreement with MedImmune 44

Shionogi Enters Into Licensing Agreement With Janssen Pharma 45

Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 46

Mundipharma Enters Into Licensing Agreement With Shionogi 47

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 48

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 49

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 50

Equity Offering 51

PharmaIN to Raise USD17 Million in Private Placement of Shares 51

Egalet Completes Private Placement Of Shares For USD 15 Million 52

Debt Offering 53

Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 53

Asset Transactions 54

Kyowa Pharma to Acquire 21 Products from Shionogi 54

Pragma Pharma Acquires Keflex from Shionogi 55

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 56

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 57

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58

Merz Pharma Acquires Cuvposa from Shionogi 59

Shionogi & Co Ltd-Key Competitors 60

Shionogi & Co Ltd-Key Employees 61

Shionogi & Co Ltd-Locations And Subsidiaries 64

Head Office 64

Other Locations & Subsidiaries 64

Joint Venture 66

Recent Developments 67

Strategy And Business Planning 67

Apr 23, 2018: Shionogi Announces Establishment Of New Manufacturing Subsidiary In Japan 67

Feb 07, 2017: Shionogi to Announce Corporate Reorganization and Personnel Reassignment 68

Financial Announcements 72

Jul 30, 2018: Shionogi: Financial Results for the First Quarter of Fiscal Year 2018(Consolidated) 72

May 09, 2018: Shionogi : Financial Results for Fiscal Year 2017 73

Feb 05, 2018: Shionogi: Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) 75

Jul 31, 2017: Shionogi Reports Revenue Of JPY75 Billion In Q1 Fiscal 2018 76

May 10, 2017: Shionogi Reports Revenue Of JPY338.9 Billion In Fiscal 2016 77

Feb 02, 2017: Shionogi Reports Revenue Of JPY256.5 Billion In Third Quarter Ended December 31, 2016 78

Corporate Communications 79

Mar 19, 2018: Shionogi to Announce Executive Appointments 79

Mar 21, 2017: Shionogi to Announce Executive Appointments 80

Product News 81

10/04/2017: Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 81

06/01/2017: Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe Meeting 83

04/22/2017: Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin 85

04/18/2018: Shionogi to Present New Data on COT-143 at 2018 European Congress of Clinical Microbiology and Infectious Diseases 87

03/23/2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 88

01/12/2017: Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 89

Product Approvals 90

Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan 90

Clinical Trials 91

May 30, 2018: Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating KPS-0373 (Development Code) for the Treatment of Spinocerebellar Ataxia 91

Mar 05, 2018: OncoTherapy Science: Announcement of the progress of Phase III clinical study of the cancer-specific peptide vaccine S-588410 92

Sep 28, 2017: Shionogi to Highlight Research on Cefiderocol (S-649266), A Siderophore Cephalosporin at IDWeek 2017 93

Jun 30, 2017: Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410 95

Apr 17, 2017: Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin at the 27th European Congress of Clinical Microbiology and Infectious Diseases 96

Other Significant Developments 98

Sep 12, 2018: Shionogi to announce corporate reorganization 98

Feb 28, 2018: Shionogi to Announce Corporate Reorganizations 99

Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 100

Appendix 101

Methodology 101

About GlobalData 101

Contact Us 101

Disclaimer 101


List Of Figure

List of Figures

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shionogi & Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17

Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18

Kyoto University and Shionogi Enter into Research Agreement 19

DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20

PharmaIN Enters into Agreement with Shionogi 21

Shionogi and UMN Pharma Enter into Agreement 22

Clinigen Enters into Agreement with Shionogi 23

Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25

FunPep Enters into Research Agreement with Shionogi 27

Shionogi Enters into Research Agreement with NB Health Labs 28

Shionogi Enters into Research Agreement with Nissan Chemical Industries 29

Mundipharma Enters into Distribution Agreement with Shionogi 30

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32

Shionogi to Enter into Agreement with TB Alliance 33

Kyoto University and Shionogi Enter into R&D Agreement 34

Shionogi Enters into Licensing Agreement with Rohto Pharma 35

Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 36

Pharmbio Korea Enters into Licensing Agreement with Shionogi 37

Ophirex Enters into Licensing Agreement with Eli Lilly and Shionogi 38

Duchesnay Receives Rights for Osphena from Shionogi 39

Shionogi Enters into Licensing Agreement with University of Tokushima 40

F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 41

Shionogi Enters into Licensing Agreement with PeptiDream 42

Shionogi Enters into Licensing Agreement with FunPep 43

Shionogi Enters into Licensing Agreement with MedImmune 44

Shionogi Enters Into Licensing Agreement With Janssen Pharma 45

Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 46

Mundipharma Enters Into Licensing Agreement With Shionogi 47

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 48

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 49

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 50

PharmaIN to Raise USD17 Million in Private Placement of Shares 51

Egalet Completes Private Placement Of Shares For USD 15 Million 52

Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 53

Kyowa Pharma to Acquire 21 Products from Shionogi 54

Pragma Pharma Acquires Keflex from Shionogi 55

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 56

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 57

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58

Merz Pharma Acquires Cuvposa from Shionogi 59

Shionogi & Co Ltd, Key Competitors 60

Shionogi & Co Ltd, Key Employees 61

Shionogi & Co Ltd, Other Locations 64

Shionogi & Co Ltd, Subsidiaries 65

Shionogi & Co Ltd, Joint Venture 66

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Shionogi & Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Shionogi & Co Ltd (Shionogi) focuses on the research, development, manufacturing and marketing of pharmaceutical products, diagnostic reagents and medical devices. The company's core pharmaceuticals product business offers drugs for the treatment of disorders in the areas of metabolism, infection, immunity and cancer pain. Shionogi also sells, distributes and provides information about diagnostic products in the fields of infectious diseases, cardiovascular diseases and allergies. The company operates a network of subsidiaries, branches, sales offices manufacturing plants and research laboratories across Japan, China, Taiwan, North America and Europe. Shionogi is headquartered in Osaka, Japan.

Shionogi & Co Ltd (4507)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17

Venture Financing 17

Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17

Partnerships 18

Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18

Kyoto University and Shionogi Enter into Research Agreement 19

DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20

PharmaIN Enters into Agreement with Shionogi 21

Shionogi and UMN Pharma Enter into Agreement 22

Clinigen Enters into Agreement with Shionogi 23

Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25

FunPep Enters into Research Agreement with Shionogi 27

Shionogi Enters into Research Agreement with NB Health Labs 28

Shionogi Enters into Research Agreement with Nissan Chemical Industries 29

Mundipharma Enters into Distribution Agreement with Shionogi 30

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32

Shionogi to Enter into Agreement with TB Alliance 33

Kyoto University and Shionogi Enter into R&D Agreement 34

Licensing Agreements 35

Shionogi Enters into Licensing Agreement with Rohto Pharma 35

Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 36

Pharmbio Korea Enters into Licensing Agreement with Shionogi 37

Ophirex Enters into Licensing Agreement with Eli Lilly and Shionogi 38

Duchesnay Receives Rights for Osphena from Shionogi 39

Shionogi Enters into Licensing Agreement with University of Tokushima 40

F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 41

Shionogi Enters into Licensing Agreement with PeptiDream 42

Shionogi Enters into Licensing Agreement with FunPep 43

Shionogi Enters into Licensing Agreement with MedImmune 44

Shionogi Enters Into Licensing Agreement With Janssen Pharma 45

Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 46

Mundipharma Enters Into Licensing Agreement With Shionogi 47

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 48

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 49

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 50

Equity Offering 51

PharmaIN to Raise USD17 Million in Private Placement of Shares 51

Egalet Completes Private Placement Of Shares For USD 15 Million 52

Debt Offering 53

Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 53

Asset Transactions 54

Kyowa Pharma to Acquire 21 Products from Shionogi 54

Pragma Pharma Acquires Keflex from Shionogi 55

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 56

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 57

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58

Merz Pharma Acquires Cuvposa from Shionogi 59

Shionogi & Co Ltd-Key Competitors 60

Shionogi & Co Ltd-Key Employees 61

Shionogi & Co Ltd-Locations And Subsidiaries 64

Head Office 64

Other Locations & Subsidiaries 64

Joint Venture 66

Recent Developments 67

Strategy And Business Planning 67

Apr 23, 2018: Shionogi Announces Establishment Of New Manufacturing Subsidiary In Japan 67

Feb 07, 2017: Shionogi to Announce Corporate Reorganization and Personnel Reassignment 68

Financial Announcements 72

Jul 30, 2018: Shionogi: Financial Results for the First Quarter of Fiscal Year 2018(Consolidated) 72

May 09, 2018: Shionogi : Financial Results for Fiscal Year 2017 73

Feb 05, 2018: Shionogi: Financial Results for the Third Quarter of Fiscal Year 2017(Consolidated) 75

Jul 31, 2017: Shionogi Reports Revenue Of JPY75 Billion In Q1 Fiscal 2018 76

May 10, 2017: Shionogi Reports Revenue Of JPY338.9 Billion In Fiscal 2016 77

Feb 02, 2017: Shionogi Reports Revenue Of JPY256.5 Billion In Third Quarter Ended December 31, 2016 78

Corporate Communications 79

Mar 19, 2018: Shionogi to Announce Executive Appointments 79

Mar 21, 2017: Shionogi to Announce Executive Appointments 80

Product News 81

10/04/2017: Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017 81

06/01/2017: Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe Meeting 83

04/22/2017: Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S-649266), a Siderophore Cephalosporin 85

04/18/2018: Shionogi to Present New Data on COT-143 at 2018 European Congress of Clinical Microbiology and Infectious Diseases 87

03/23/2017: FDA Approves Symproic (naldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain 88

01/12/2017: Shionogi Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 89

Product Approvals 90

Mar 30, 2017: Symproic (naldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan 90

Clinical Trials 91

May 30, 2018: Kissei Announces Negative Topline Results from the additional phase III Clinical Trial evaluating KPS-0373 (Development Code) for the Treatment of Spinocerebellar Ataxia 91

Mar 05, 2018: OncoTherapy Science: Announcement of the progress of Phase III clinical study of the cancer-specific peptide vaccine S-588410 92

Sep 28, 2017: Shionogi to Highlight Research on Cefiderocol (S-649266), A Siderophore Cephalosporin at IDWeek 2017 93

Jun 30, 2017: Announcement of milestone payment for the progress of Phase III clinical trial of the cancer-specific peptide vaccine S-588410 95

Apr 17, 2017: Shionogi to Present New Data on Cefiderocol (S-649266), a Siderophore Cephalosporin at the 27th European Congress of Clinical Microbiology and Infectious Diseases 96

Other Significant Developments 98

Sep 12, 2018: Shionogi to announce corporate reorganization 98

Feb 28, 2018: Shionogi to Announce Corporate Reorganizations 99

Mar 22, 2017: PeptiDream Announces 1st Milestone from Macrocyclic Peptide Drug Discovery Alliance with Shionogi 100

Appendix 101

Methodology 101

About GlobalData 101

Contact Us 101

Disclaimer 101


List Of Figure

List of Figures

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13


List Of Table

List of Tables

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Shionogi & Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Shionogi & Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11

Shionogi & Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

Shionogi & Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Nemesis Bioscience Raises USD1.8 Million in Seed Funding 17

Sage Therapeutics and Shionogi Enter into Co-Development Agreement 18

Kyoto University and Shionogi Enter into Research Agreement 19

DeNA and DeNA Life Science Enter into Research Partnership with Asahi Kasei Pharma and Shionogi 20

PharmaIN Enters into Agreement with Shionogi 21

Shionogi and UMN Pharma Enter into Agreement 22

Clinigen Enters into Agreement with Shionogi 23

Sekisui Chemical, PeptiDream and Shionogi to Form Joint Venture 24

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 25

FunPep Enters into Research Agreement with Shionogi 27

Shionogi Enters into Research Agreement with NB Health Labs 28

Shionogi Enters into Research Agreement with Nissan Chemical Industries 29

Mundipharma Enters into Distribution Agreement with Shionogi 30

Noven Pharma Enters Into Co-Promotion Agreement With Shionogi For Brisdelle Capsules 31

ViiV Healthcare And Shionogi Enter Into Co-Promotion Agreement For Dolutegravir 32

Shionogi to Enter into Agreement with TB Alliance 33

Kyoto University and Shionogi Enter into R&D Agreement 34

Shionogi Enters into Licensing Agreement with Rohto Pharma 35

Shionogi Enters into Licensing Agreement with Hsiri Therapeutics 36

Pharmbio Korea Enters into Licensing Agreement with Shionogi 37

Ophirex Enters into Licensing Agreement with Eli Lilly and Shionogi 38

Duchesnay Receives Rights for Osphena from Shionogi 39

Shionogi Enters into Licensing Agreement with University of Tokushima 40

F. Hoffmann-La Roche Enters into Licensing Agreement with Shionogi 41

Shionogi Enters into Licensing Agreement with PeptiDream 42

Shionogi Enters into Licensing Agreement with FunPep 43

Shionogi Enters into Licensing Agreement with MedImmune 44

Shionogi Enters Into Licensing Agreement With Janssen Pharma 45

Shionogi Enters Into Licensing Agreement With OncoTherapy Science For Cancer Peptide Vaccines 46

Mundipharma Enters Into Licensing Agreement With Shionogi 47

Plethora Solutions Enters Into Commercialization Agreement With Shionogi For PSD502 48

Concordia Pharma And Shionogi Enter Into Licensing Agreement For Ulesfia 49

Dainippon Sumitomo Pharma Enters Into Licensing Agreement With Shionogi For DSP-8153 50

PharmaIN to Raise USD17 Million in Private Placement of Shares 51

Egalet Completes Private Placement Of Shares For USD 15 Million 52

Shionogi Announces Public offering of Convertible Bonds Due 2019 for USD168.5 Million 53

Kyowa Pharma to Acquire 21 Products from Shionogi 54

Pragma Pharma Acquires Keflex from Shionogi 55

Alvogen Acquires Rights Of Naprelan Tablets From Shionogi 56

Concordia Pharma Acquires Rights To Three US Pediatrics From Shionogi 57

ViiV Healthcare Acquires Integrase Inhibitor Portfolio Of Shionogi 58

Merz Pharma Acquires Cuvposa from Shionogi 59

Shionogi & Co Ltd, Key Competitors 60

Shionogi & Co Ltd, Key Employees 61

Shionogi & Co Ltd, Other Locations 64

Shionogi & Co Ltd, Subsidiaries 65

Shionogi & Co Ltd, Joint Venture 66

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Shionogi & Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.